therapeutic action: anxiolytic effects

Study protocol for ‘Psilocybin in patients with fibromyalgia: brain biomarkers of action’

mycolabadmin

Researchers are testing whether psilocybin (the active compound in magic mushrooms) combined with therapeutic support can help people with fibromyalgia, a chronic pain condition. The study will measure brain activity using EEG and brain imaging to understand how psilocybin might reduce pain and improve mental health. Twenty patients will receive guided psilocybin sessions over eight weeks while researchers track changes in brain function and pain levels.

Read More »

Therapeutic and legal aspects of psilocybin in cancer-related depression

mycolabadmin

This paper examines how psilocybin, a naturally occurring psychoactive compound from mushrooms, could help cancer patients—especially those with head and neck cancer—who develop severe depression after surgery. Unlike traditional antidepressants that take weeks to work, psilocybin acts within hours, making it potentially ideal for patients needing rapid mental health support following disfiguring surgical procedures. However, while psilocybin is legal for medical or research use in several countries like Australia and Portugal, it remains restricted in Poland and many other places, creating legal barriers to its clinical implementation.

Read More »

Molecular insights into the modulation of the 5HT 2A receptor by serotonin, psilocin, and the G protein subunit Gqα

mycolabadmin

This study uses computer simulations to understand how psilocin (the active compound in magic mushrooms) and serotonin interact with a brain receptor called 5HT 2A R. The research shows that both molecules prefer to bind to a deeper part of the receptor rather than a shallower area, and that a protein called Gqα is essential for keeping the receptor in its active state. These findings could help scientists develop better medicines for depression and anxiety.

Read More »

The development of psilocybin therapy for treatment-resistant depression: an update

mycolabadmin

Psilocybin, a compound found in certain mushrooms, is being studied as a potential treatment for severe depression that doesn’t respond to standard medications. In clinical trials, patients receiving psilocybin alongside psychological support showed significant improvement in depressive symptoms within days to weeks, with benefits lasting for months. Unlike daily antidepressant pills, psilocybin therapy involves one or more carefully supervised dosing sessions in a hospital setting with therapeutic support before and after. Larger studies are underway to confirm its effectiveness and safety before it could potentially become an approved treatment.

Read More »

Chemical Composition and Biological Activities of Psilocybe Mushrooms: Gaps and Perspectives

mycolabadmin

This comprehensive review examined what we know about Psilocybe mushrooms, which are known for their mind-altering effects due to compounds called psilocybin and psilocin. The study found that while these mushrooms show promise for treating depression and anxiety, most research has focused only on their psychoactive properties. The review identified over 30 chemical compounds in these mushrooms and noted that some species show potential antimicrobial and antioxidant properties. The authors emphasize that much more research is needed to explore other potential health benefits and to understand exactly how individual compounds work in the body.

Read More »

Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming

mycolabadmin

Researchers tested whether psilocybin (the active compound in magic mushrooms) could treat obsessive-compulsive disorder using genetically modified mice that exhibit excessive grooming similar to OCD in humans. A single dose of psilocybin or psychedelic mushroom extract significantly reduced the excessive grooming behavior and anxiety in these mice, with benefits lasting up to six weeks. These findings suggest psilocybin may be a promising new treatment for OCD in humans, offering longer-lasting effects from a single dose compared to current medications.

Read More »
Scroll to Top